|
|
(PQA2) Impact of obesity on endogenous mutational hotspots
|
5R21CA185508-02
|
$168,019
|
$168,019
|
VASQUEZ, KAREN
|
UNIVERSITY OF TEXAS, AUSTIN
|
|
|
(PQD1) Treatment-emergent resistance to NEDD8-activating enzyme inhibition
|
5R01CA180150-03
|
$558,328
|
$558,328
|
PETROSKI, MATTHEW
|
SANFORD-BURNHAM MEDICAL RESEARCH INSTIT
|
|
|
(PQD5) A novel genetic strategy to predict efficacy of anti-CD20 antibodies
|
7R01CA185372-02
|
$335,822
|
$335,822
|
RICHARDS, KRISTY
|
CORNELL UNIVERSITY
|
|
|
(PQD5)Biomaterials-based Adaptive Tumor Microenvironments for In Vitro Drug Scree
|
5R21CA185236-02
|
$215,652
|
$215,652
|
SINGH, ANKUR
|
CORNELL UNIVERSITY
|
|
|
A cohort study among workers exposed to benzene in China
|
ZIA CP010120 - 02060
|
$164,963
|
$32,993
|
Rothman, Nathaniel
|
DCEG (NCI)
|
|
|
A Fourth Outcome: DNA Damage and the Differentiation of B Cells
|
5R01CA156674-05
|
$314,884
|
$314,884
|
TEITELL, MICHAEL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
|
A Modifier of Plasmacytoma Susceptibility Maps to Mouse Chr 1
|
ZIA BC 011064
|
$109,366
|
$21,873
|
Mock, Beverly
|
CCR (NCI)
|
|
|
A multi-center international hospital-based case-control study of lymphoma in Asi
|
ZIA CP010136 - 10512
|
$3,592,270
|
$3,592,270
|
Lan, Qing
|
DCEG (NCI)
|
|
|
A MULTILEVEL APPROACH TO ENERGY BALANCE AND CANCER ACROSS THE LIFECOURSE
|
5U54CA155496-05
|
$1,739,060
|
$469,546
|
COLDITZ, GRAHAM
|
WASHINGTON UNIVERSITY
|
|
|
A new small molecule targeting agent and therapeutic for non-Hodgkin's lymphoma
|
5R44CA159843-03
|
$740,587
|
$740,587
|
BALHORN, RODNEY
|
SHAL TECHNOLOGIES, INC.
|
|
|
A New Treatment Paradigm for ALK-Driven Cancers Exploiting Oncogene Overdose
|
7R01CA190696-02
|
$312,436
|
$312,436
|
SCHATZ, JONATHAN
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
|
A Novel Multimodality Immune Based Platform in Advanced Mycosis Fungoides
|
5R03CA184127-02
|
$84,750
|
$84,750
|
DIEFENBACH, CATHERINE
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
|
A novel NKG2D-specific BiTE cancer immunotherapy
|
5R01CA164178-03
|
$336,150
|
$168,075
|
SENTMAN, CHARLES
|
DARTMOUTH COLLEGE
|
|
|
A Pathway of Tumor Suppression
|
5R01CA047296-27
|
$249,580
|
$82,361
|
LOZANO, GUILLERMINA
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
|
A Phase I Study of rHuIL-12 as an Immunotherapy and Radiomitigator for CTCL Patie
|
1R44CA192576-01
|
$1,088,333
|
$1,088,333
|
BASILE, LENA
|
NEUMEDICINES, INC.
|
|
|
A Phase I/II Clinical Trial to Investigate Fucosylated Tregs in Prevention of GVH
|
1R44CA192601-01A1
|
$1,059,489
|
$529,745
|
BUI, LYNNE
|
TARGAZYME, INC.
|
|
|
A prospective analysis of peripheral blood cytokines and non-Hodgkin lymphoma
|
5R01CA149445-05
|
$738,521
|
$738,521
|
BIRMANN, BRENDA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
A Role for KSHV in the Pathogenesis of Malignancies
|
ZIA SC 010356
|
$247,753
|
$24,775
|
Tosato, Giovanna
|
CCR (NCI)
|
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-39S1
|
$62,498
|
$1,875
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-39S2
|
$125,000
|
$3,750
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Abramson Cancer Center Support Grant
|
5P30CA016520-39
|
$7,704,373
|
$231,131
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Activation of Proto-Oncogenes by Chromosomal Translocation
|
ZIA SC 010378
|
$522,314
|
$261,157
|
Aplan, Peter
|
CCR (NCI)
|
|
|
Addressing Herpesvirus-associated Cancers through the UNC-Malawi Cancer Consortiu
|
5U54CA190152-02
|
$699,896
|
$321,952
|
GOPAL, SATISH
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
|
Adult Leukemia Research Center
|
5P01CA018029-40
|
$4,225,448
|
$380,290
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Agricultural Cohort Consortium
|
ZIA CP010119 - 10537
|
$74,872
|
$11,231
|
Beane Freeman, Laura
|
DCEG (NCI)
|
|
|
AIDS Malignancy Consortium (AMC)
|
2UM1CA121947-09
|
$13,134,493
|
$3,283,623
|
MITSUYASU, RONALD
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-02S1
|
$34,176
|
$1,709
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-02S2
|
$810,357
|
$40,518
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
5U10CA180821-02
|
$9,967,453
|
$498,373
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor
|
ZIA BC 011415
|
$145,193
|
$47,914
|
Kochenderfer, James
|
CCR (NCI)
|
|
|
Allotransplant for DOCK8 deficiency
|
ZIA BC 011374
|
$406,393
|
$203,196
|
Hickstein, Dennis
|
CCR (NCI)
|
|
|
Alpha Radioimmunotherapy for Lymphoma Treatment
|
5R01CA172582-03
|
$634,846
|
$634,846
|
SANDMAIER, BRENDA
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Alternative End-Joining in DNA Repair and Chromosomal Translocations
|
5F30CA189740-02
|
$35,829
|
$35,829
|
KUMAR, VIPUL
|
HARVARD MEDICAL SCHOOL
|
|
|
Ambient dioxin exposure and cancer risk in women (IWHS and AHS)
|
ZIA CP010125 - 10712
|
$100,308
|
$20,062
|
Jones, Rena
|
DCEG (NCI)
|
|
|
An Early-Phase Clinical Trial Evaluating ABC294640 in Patients with Refractory/Re
|
5R42CA183708-04
|
$499,411
|
$499,411
|
PARSONS, CHRISTOPHER
|
APOGEE BIOTECHNOLOGY CORPORATION
|
|
|
Analysis of the role of the SWI/SNF complex in tumor suppression
|
5R01CA172152-03
|
$359,256
|
$179,628
|
ROBERTS, CHARLES
|
DANA-FARBER CANCER INST
|
|
|
Anatomic Pathology Residency Program
|
ZIE BC 011384
|
$1,007,151
|
$100,715
|
Oberholtzer, J.
|
CCR (NCI)
|
|
|
Animal Model and Genotyping Core Support Facility
|
ZIC BC 011047
|
$1,054,639
|
$210,928
|
DuBois, Wendy
|
CCR (NCI)
|
|
|
Antibody-interferon fusion proteins for treatment of B-cell malignancies
|
5R01CA162964-05
|
$319,550
|
$319,550
|
MORRISON, SHERIE
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
|
Anticancer drug-induced BH3-only protein.Bak interactions
|
5R01CA166741-04
|
$321,459
|
$321,459
|
KAUFMANN, SCOTT
|
MAYO CLINIC ROCHESTER
|
|
|
Antigen-specific T cell Redirectors, ATR, for immunotherapy
|
1R21CA185819-01A1
|
$176,175
|
$176,175
|
SCHNECK, JONATHAN
|
JOHNS HOPKINS UNIVERSITY
|
|
|
Apoptosis Mechanisms and Human Cancer
|
5R01CA082197-16
|
$249,040
|
$174,328
|
WANG, HONG-GANG
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
3P30CA023074-35S5
|
$1,917,600
|
$115,056
|
KRAFT, ANDREW
|
UNIVERSITY OF ARIZONA
|
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
3P30CA023074-35S6
|
$50,000
|
$3,000
|
KRAFT, ANDREW
|
UNIVERSITY OF ARIZONA
|
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
3P30CA023074-35S7
|
$124,932
|
$7,496
|
KRAFT, ANDREW
|
UNIVERSITY OF ARIZONA
|
|
|
ATBC Lymphoma Studies
|
ZIA CP010195 - 10733
|
$1,285
|
$642
|
Berndt, Sonja
|
DCEG (NCI)
|
|
|
ATBC Study
|
ZIA CP010195 - 03031
|
$871,993
|
$69,759
|
Albanes, Demetrius
|
DCEG (NCI)
|
|
|
Autoimmune Conditions, Genetic Variations, and Lymphoma Etiology
|
5R03CA179558-02
|
$84,000
|
$84,000
|
WANG, SOPHIA
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
|
Autologous T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor
|
ZIA BC 011413
|
$36,298
|
$27,224
|
Kochenderfer, James
|
CCR (NCI)
|
|
|
Automated Ultrasensitive Detection of Light Chain Restriction in Lymphoproliferat
|
5R44CA168019-03
|
$529,530
|
$529,530
|
MA, XIAO-JUN
|
ADVANCED CELL DIAGNOSTICS, INC.
|
|
Total relevant funding to Non Hodgkins Lymphoma for this search: $122,363,118
|
